A method of reducing circulating levels of the pro-inflammatory cytokines tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6) in a human subject in need thereof by 25% to 50%, the method comprising:
- administering to the subject a course of therapy that includes oral consumption of a cannabinoid preparation periodically or every day for at least 20 days;
- wherein cannabinoids contained in the preparation are in a form that consists essentially of micelles suspended in an aqueous solvent;
- wherein the micelles in the preparation comprise one or more amphipathic compounds combined with full-spectrum hemp oil;
- wherein the preparation has a cannabinoid content of 0.1 to 1.0% by weight,
- wherein the cannabinoid content is a mixture of cannabinoids that includes at least 70% cannabidiol (CBD), at least 2% tetrahydrocannabivarin (THCV), at least 3% cannabidivarin, and less than 1% Δ9-tetrahydrocannabinolic acid (THC);
- wherein the course of therapy with the cannabinoid preparation results in a reduction in the circulating levels of the subject of both the TNFα and the IL-6.